SETDB1 and breast carcinoma: AKT1E17K occurs in breast cancer, bladder cancer, endometrial cancer, colorectal cancer and acute lymphoblastic leukemia, etc.[7, 8] In breast cancer, AKT1E17K has been identified in 2% to 7% of patients and associated with poor prognosis.[9] In non‐small cell lung carcinoma, AKT1E17K enhances K64 methylation by SETDB1, leading to its hyper‐activation and promotes tumor development.[10] However, the oncogenic potential of this mutation in different cell contexts is controversial.